Want to join the conversation?
$LLY 3Q15 total OpEx declined by 7% or over $200MM YoverY. R&D expense declined 10%, driven by 2014 charge associated with the termination of tabalumab development and favorable FX rate impact. By geography, US pharma revenue was up 13%, driven by volume, partially offset by price.
People seem to be cold about the $HAL earnings! Honestly, I expected more stock action by now.
$TSLA's Musk says Neuralink will take on AI prominence. Apparently, he wants to avoid a "Terminator" kind situation.
$JCP shares rebounded and now in green territory after saying it will hire 800 consultants as part of a beauty expansion that will include 70 new Sephora store-in-store locations.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.